The aim of the present invention is to provide an application of directional killing of human bladder cancer cell T24 with CD3 *B7H3 bispecific antibody. Specifically, the application of CD3 *B7H3 bispecific antibody can enhance the killing effect of activated T cells (ATC) on bladder cancer cell T24, and provide a new target for targeted therapy of bladder cancer. The invention proves that B7H3 is highly expressed in T24 bladder cancer cells by research, and that the ability of ATC combined with CD3 *B7H3 bispecific antibody directionally kills T24 bladder cancer cells is enhanced compared with untouched CD3 *B7H3 bispecific antibody ATC, which has significant cytotoxic activity to T24 bladder cancer cells. When ATC combined with CD3 *B7H3 bispecific antibody was co-cultured with tumor cells at a target-to-effect ratio of 10:1, the killing effect increased significantly. Meanwhile, the levels of interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) secreted by ATC combined with CD3 *B7H3 bispecific antibody increased.
【技术实现步骤摘要】
关于CD3×B7H3双特异性抗体定向杀伤膀胱癌细胞T24的应用
本专利技术的目的在于提供一种偶联CD3×B7H3双特异性抗体定向杀伤人膀胱癌细胞T24的应用，具体为偶联CD3×B7H3双特异性抗体可增强活化T细胞（ATC）对T24膀胱癌细胞的杀伤作用，为膀胱癌的靶向治疗提供新的免疫治疗靶点。
技术介绍
膀胱癌是男性中第四常见的癌症，女性中第11常见的癌症。2017年在美国估计有79030例新发膀胱癌病例和19870例死亡病例，其中男性发病率和死亡率高于女性4倍。最初，约85%的膀胱癌患者被诊断为浅表性膀胱癌，超过50%的浅表性膀胱癌会复发，并且，仅有46%的三期患者和15%的4期患者可以达到五年生存。因此，膀胱癌患者所面临的形式非常严峻。尽管存在多种治疗方法，比如说手术，放疗，化疗，膀胱癌的术后生存率依旧很不理想。这些治疗方法可以限制肿瘤的发展及生长，但它们无法遏制肿瘤的复发和耐药的产生。因此，发展新的疗法对膀胱癌患者是至关重要的。随着免疫学的研究进展，免疫治疗被公认为二十一世纪肿瘤综合治疗模式中第四种治疗方法。例如，靶向CTLA-4（细胞毒性T淋巴细胞抗原4）和...
【技术保护点】
1.偶联CD3×B7H3双特异性抗体定向杀伤人膀胱癌细胞的应用。
【技术特征摘要】
1.偶联CD3×B7H3双特异性抗体定向杀伤人膀胱癌细胞的应用。2.根据权利要求1所述的应用，其特征在于，所述膀胱癌细胞为T24膀胱癌细胞。3.根据权利要求1所述的应用，其特征在于，偶联CD3×B7H3双特异性抗体的结构如图1。4.根据权利要求3所示的应用，其特征在于，双特异性...
还没有人留言评论。发表了对其他浏览者有用的留言会获得科技券。